Home › Rhabdomyosarcoma › District of Columbia › Washington
Rhabdomyosarcoma clinical trials in Washington, DC
5 studies for Rhabdomyosarcoma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RecruitingPhase 1
- Children's National Hospital, Washington D.C.
- Childrens National Hospital, Washington D.C.
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Recruiting
- Sibley Memorial Hospital, Washington D.C.
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
- Children's National Medical Center, Washington D.C.
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RecruitingPhase 2
- Children's National Medical Center, Washington D.C.
Rhabdomyosarcoma trials in other cities
- Houston, TX6 studies
- Memphis, TN6 studies
- Salt Lake City, UT4 studies
- Philadelphia, PA4 studies
- Boston, MA4 studies
- Seattle, WA3 studies
- Dallas, TX3 studies
- Birmingham, AL3 studies
- The Bronx, NY3 studies
- Baltimore, MD3 studies
- Aurora, CO3 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.